Pharmaceutical group Adcock Ingram has reported lower profits at the halfway stage of the financial year, with the group’s operational and financial performance affected by sector-specific factors.

Revenue for the six months to end-December decreased 0.6% to R4.7bn, due to a slowdown in both the independent and pharmaceutical wholesale channels, the latter having reduced their average inventory holdings on a number of key brands, the group said on Thursday...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.